BRAF and melanoma: Finally, analyzing biopsies from BRAFV600E mutant melanoma patients (n = 4) who had progressed upon vemurafenib treatment, these authors found that PTPN11 phosphorylation at Y542 can serve as a biomarker to identify tumors with RTK-driven acquired resistance to BRAF inhibitors.